Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4.
- Nat. Commun., Sep 06 2023, 14 (1) | https://doi.org/10.1038/s41467-023-40829-2